Artwork
iconShare
 
Manage episode 494638553 series 3256997
Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Sagar Lonial, MD, FACP, discuss key topics with CELMoD therapy for multiple myeloma, including:

  • Mechanistic differences between CELMoDs and IMiDs
  • Emerging data with CELMoDs and their potential therapeutic roles across the disease continuum of multiple myeloma
  • The clinical implications of MRD negativity as a surrogate marker of long-term outcomes in clinical trials in multiple myeloma

Presenters:

Jesus Berdeja, MD
Director of Myeloma Research
Greco-Hainsworth Centers for Research
Tennessee Oncology
Nashville, Tennessee

Amrita Krishnan, MD, FACP
Director, Judy and Bernard Briskin Center for Myeloma
Executive Director of Hematology
City of Hope Orange County
Professor of Hematology/HCT
City of Hope Cancer Center
Irvine, California

Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University
Atlanta, Georgia

Content based on an online CME program supported by an independent educational grant from Bristol Myers Squibb.

Link to full program:
https://bit.ly/3IwbslQ


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

  continue reading

211 episodes